Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIN-ATTACK-FMF: On-demand anakinra for colchicine-resistant familial Mediterranean fever attacks
2023-506721-11-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Familial Mediterranean fever (FMF) comparing On-demand anakinra with Standard of care (usual analgesics) (2 arms). Primary endpoint: Primary: mean number of painful days per month at 6 months of treatment. Planned start Feb 2024; status: authorised.
02
Drugs
anakinra
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on 2023-506721-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506721-11-00.